You are here

Generic Version of Tambocor Gains FDA Approval

PRINCETON, N.J., March 31 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to market Flecainide Acetate Tablets USP, in 50 mg, 100 mg, and 150 mg strengths. The Division of Bioequivalence has determined Ranbaxy's Flecainide Acetate Tablets USP, 50 mg, 100 mg, and 150 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug Tambocor(TM) Tablets, 50 mg, 100 mg, and 150 mg, respectively, of 3M Pharmaceuticals, Inc.

In patients without structural heart disease, Tambocor(TM) is indicated for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms, paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Tambocor(TM) is also indicated for the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening. In 2002, the total sales of Flecainide Acetate Tablets totaled $105.6 million (IMS - MAT, Dec. 2002).

Product is expected to be available through wholesalers and other distribution outlets to dispensing pharmacies throughout the United States. According to Mr. Dipak Chattaraj, President of Ranbaxy Pharmaceuticals Inc., "With the addition of Flecainide Acetate Tablets, Ranbaxy's generic product line is expanding to meet the clinical needs of the U.S. Healthcare System that includes prescribers, patients and health plans with a generic alternative for this cardiovascular product. Flecainide will be manufactured in the U.S. at Ohm Laboratories, our facility located in North Brunswick, NJ."

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs